ImmuCell Corporation announced its unaudited financial results for the first quarter ended March 31, 2025. The company reported a 11% increase in product sales, reaching approximately $8.1 million compared to the first quarter of 2024. For the six-month period ended March 31, 2025, product sales rose by 28% to approximately $15.8 million compared to the same period in 2024. Over the twelve-month period, product sales also increased by 28% to approximately $27.3 million. Net income for the first quarter of 2025 set a new quarterly record at approximately $1.4 million, surpassing the previous record of $584,000 set during the first quarter of 2017. Earnings per diluted share were reported at $0.16. The gross margin earned during the three-month period ended March 31, 2025, was 42%, up from 32% in the corresponding period of 2024. Adjusted EBITDA improved to approximately $2.3 million for the three-month period, $3.7 million for the six-month period, and $3.3 million for the twelve-month period ended March 31, 2025. ImmuCell is also focused on reducing product development expenses and exploring strategic options for its technology. The company is working to reduce its order backlog and improve gross margins, with the gross margin for the first quarter of 2025 improving from 37% recorded in the fourth quarter of 2024. Additionally, ImmuCell is progressing with the Investigational Product use of Re-Tain® to gather market feedback in the second half of 2025.